Despite the high efficacy of everolimus for treating HR-positive advanced breast cancer, it can result in serious adverse effects, including interstitial pneumonia, infections, stomatitis, delayed wound healing, and hyperglycemia, because mTOR inhibition suppresses basic cellular processes. Here, MTOR is linked to breast cancer.